News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Subscribe To Our Newsletter & Stay Updated
